Edito
Author:
Dr. Claire Labreveux - Director of the R&D Department of Unicancer
Unicancer, a pioneer in personalized medicine, has developed for several years, as part of its research strategy, a research program on circulating tumor DNA.
Author:
French Breast Cancer Intergroup Unicancer
PADA-1 trial : changing hormone therapy following early detection of ESR1 mutations can delay the onset of cancer resistance to standard therapy.
Author:
Nicholas Turner, The Institute of Cancer Research (UK)
TRAK-ER: potential benefits of molecular relapse monitoring with ctDNA assays in patients with ER positive HER2 negative breast cancer on adjuvant endocrine therapy.
Author:
Unicancer - UCGI group
PANIRINOX : evaluating FOLFIRINOX + Panitumumab vs mFOLFOX6 + Panitumumab in patients with unresectable metastatic colorectal cancer B-RAF and RAS wild type.
Author:
Unicancer, Radiation oncology Group, UNITRAD
NIRVANA-Lung: evaluate predictive biomarker of overall survival in patients with advanced non-small cell lung cancer
Author:
Gustave Roussy
REVEAL: Reshape the EValuation Efficiency and Accuracy of non-small cell Lung cancer
Author:
Dr. Gudrun Schleiermacher, pediatrician and researcher at Institut Curie
A blood test to diagnose eye cancer in children
Author:
Dr Esma SAADA, Medical Oncologist - Centre Antoine Lacassagne, Nice
TARGET: Added value of liquid biopsy to tumour screening performed in the Molecular Tumour
Author:
ICM and IRCM, Montpellier
Circulating DNA research and applications : a synergistic effort by the ICM and the IRCM in Montpellier
Actualités
Actualités
28 août 2023
Le Professeur William Jacot nommé Directeur Scientifique de l’ICM
Publié par

Actualités
28 août 2023
Le Professeur William Jacot nommé Directeur Scientifique de l’ICM
Publié par

Publications







